Biomarkers to guide Lu-PSMA therapy in advanced prostate cancer
Official title: Integration of circulating tumor cell and nuclear imaging biomarkers to assess LuPSMA response and resistance in advanced prostate cancer patients
Funded at Massachusetts General Hospital · NIH-11394558 · Data updated 2026-11-12
Researchers are testing a combination of blood-based markers and tumor imaging to see who will respond to Lu-PSMA therapy and why some patients develop resistance.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 18, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $684,107 |
| NIH project number | 5R01CA302774-02 |
| Project ID | NIH-11394558 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with advanced/metastatic prostate cancer being considered for Lu-PSMA radiopharmaceutical therapy.
✕Less likely to help
Patients not eligible for Lu-PSMA therapy or those without measurable biomarker signals may see limited direct benefit.
What this research studies
This project aims to identify and use circulating tumor cell and nuclear imaging biomarkers to predict and monitor how advanced prostate cancer patients respond to Lu-PSMA radiopharmaceutical therapy. By tracking these biomarkers over time, researchers hope to better tailor treatment and detect resistance early. The study will integrate patient blood samples and PSMA-targeted imaging data to stratify responders from non-responders in a real-world clinical setting. Participation could involve blood draws and imaging assessments during treatment, with data used to guide future personalized care.
Why it matters
Potential benefit: If successful, patients could receive more effective, individualized Lu-PSMA therapy with fewer unnecessary treatments and earlier management of resistance.
How similar studies have gone: Previous work suggests liquid biopsy and imaging biomarkers can reflect treatment response in prostate cancer, supporting the potential for this approach.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Ng, Sheung Chee Thomas — Massachusetts General Hospital
- Study coordinator: Ng, Sheung Chee Thomas
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.